Back
Outlook Therapeutics Stock Price Chart
This Tech Company Grew 32,481%...
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
16
OTLK
Outlook Therapeutics
Last Price:
$1.48
Seasonality Move:
25.75%
7 Day Trial
ALL ACCESS PASS
$
7
Elon Musk Predicts MAJOR Crisis in Trump's First Year
See Why Investors are Pouring Mountains of Cash into Certain Companies Trump Wants to Solve the Problem.-
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and OTLK is experiencing slight buying pressure.
Outlook Therapeutics Price Chart Indicators
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 1.44 | Sell |
| 20-day SMA: | 1.92 | Sell |
| 50-day SMA: | 4.16 | Sell |
| 200-day SMA: | 6.7 | Sell |
| 8-day EMA: | 1.49 | Sell |
| 20-day EMA: | 2.17 | Sell |
| 50-day EMA: | 3.62 | Sell |
| 200-day EMA: | 6.73 | Sell |
Outlook Therapeutics Technical Analysis Indicators
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.86 | Sell |
| Relative Strength Index (14 RSI): | 21.05 | Sell |
| Chaikin Money Flow: | 389371 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | ( - ) | Buy |
| Bollinger Bands (100): | ( - ) | Buy |
Outlook Therapeutics Technical Analysis
| Dec 11 | Dec 12 | Dec 13 | Dec 16 | Dec 17 | Dec 18 | Dec 19 | Dec 20 | Dec 23 | Dec 24 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec | ||||||||||
| 11 | 12 | 13 | 16 | 17 | 18 | 19 | 20 | 23 | 24 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Technical Analysis for Outlook Therapeutics Stock
Is Outlook Therapeutics Stock a Buy?
-
Outlook Therapeutics share price is 1.42 while OTLK 8-day simple moving average is 1.44, which is a Sell signal.
-
The stock price of OTLK is 1.42 while Outlook Therapeutics 20-day SMA is 1.92, which makes it a Sell.
-
Outlook Therapeutics 50-day simple moving average is 4.16 while OTLK share price is 1.42, making it a Sell technically.
-
OTLK stock price is 1.42 and Outlook Therapeutics 200-day simple moving average is 6.70, creating a Sell signal.
OTLK Technical Analysis vs Fundamental Analysis
Sell
16
Outlook Therapeutics (OTLK)
is a Sell
Is Outlook Therapeutics a Buy or a Sell?
-
Outlook Therapeutics stock is rated a SellThe current Outlook Therapeutics [OTLK] share price is $1.42. The Score for OTLK is 16, which is 68% below its historic median score of 50, and infers higher risk than normal.
Outlook Therapeutics Stock Info
Market Cap:
33.6M
Price in USD:
1.42
Share Volume:
787.2K
Outlook Therapeutics 52-Week Range
52-Week High:
12.85
52-Week Low:
0.87
Sell
16
Outlook Therapeutics (OTLK)
is a Sell
Outlook Therapeutics Share Price Forecast
-
What is the Outlook Therapeutics stock price today?The Outlook Therapeutics stock price is 1.42 USD today.
-
Will OTLK stock go up or go down?Outlook Therapeutics> share price is forecast to RISE/FALL based on technical indicators
-
Is Outlook Therapeutics overvalued?According to simple moving average, exponential moving average, oscillators, and other technical indicators, Outlook Therapeutics is overvalued.
Is Outlook Therapeutics Stock a Buy?
-
Outlook Therapeutics share price is 1.42 while OTLK 8-day exponential moving average is 1.49, which is a Sell signal.
-
The stock price of OTLK is 1.42 while Outlook Therapeutics 20-day EMA is 2.17, which makes it a Sell.
-
Outlook Therapeutics 50-day exponential moving average is 3.62 while OTLK share price is 1.42, making it a Sell technically.
-
OTLK stock price is 1.42 and Outlook Therapeutics 200-day simple moving average is 6.73, creating a Sell signal.
Fundamental Analysis of Outlook Therapeutics
Is Outlook Therapeutics a good investment?
-
Analysts estimate an earnings increase this quarter of $0.39 per share, a decrease next quarter of $0.00 per share, an increase this year of $0.74 per share, and an increase next year of $1.39 per share.
Technical Analysis of Outlook Therapeutics
Should I short Outlook Therapeutics stock?
-
OTLK Moving Average Covergence Divergence (MACD) indicator is -0.86, suggesting Outlook Therapeutics is a Sell
-
Outlook Therapeutics Relative Strength Index (RSI) is 21.05, which suggest Outlook Therapeutics is oversold
-
The Bollinger Bands (25) for Outlook Therapeutics is ( - ), which suggest Outlook Therapeutics is a Buy
-
The Bollinger Bands (100) for Outlook Therapeutics is ( - ), which suggest Outlook Therapeutics is a Buy
* Outlook Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.